CyMedica Orthopedics, Inc., has commercially launched the CyMedica QB1 System for the treatment of quadriceps muscle atrophy. The CyMedica QB1 System has introduced at the Arthroscopy Association of North American Arthroscopic Society for Sports Medicine (AANA) annual meeting in Los Angeles recently.
Delivering professional athlete rehabilitation for every patient, the QB1 capitalizes on proprietary revolutionary NMES (neuromuscular electrical stimulation) technology for the treatment of quadriceps muscle atrophy and combines three best-in-class products: a postoperative knee brace, a form-fitting conductive garment, and a user friendly NMES control interface. The device substantially simplifies the delivery of "at home" NMES treatment and encourages patient compliance.
The QB1 will allow the orthopedic surgeon to treat every patient like a professional athlete by initiating neuromuscular activation immediately following knee surgery. The QB1 NMES system delivers high intensity electrical muscle stimulation while maintaining patient comfort. The QB1's proprietary closed-loop system monitors and adjusts the electrical stimulation power delivered to the patient to ensure consistent and comfortable quadriceps activation.
Subscribe to PharmaTutor News Alerts by Email >>
